• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Xywav (calcium, magnesium, potassium, and sodium oxybates)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Xywav (calcium, magnesium, potassium, and sodium oxybates)

  • Profile

Profile

Contact Information

Contact: Jazz Pharmaceuticals
Website: https://www.xywav.com/

Currently Enrolling Trials

    Show More

    Xywav (calcium, magnesium, potassium, and sodium oxybates) - 2 indications

    Scroll down for information on each indication:

    • for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy; approved July of 2020
    • for Idiopathic Hypersomnia (IH) in adults; approved August of 2021

    General Information

    Xywav (calcium, magnesium, potassium, and sodium oxybates) is a central nervous system depressant.

    Xywav is specifically indicated for the following conditions:

    • for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy
    • for the treatment of idiopathic hypersomnia (IH) in adults

    Xywav is supplied as a solution for oral administration. Scroll down for the recommended dosing/administration for each indication.

    Mechanism of Action

    Xywav is a CNS depressant. The exact mechanism of action of Xywav in the treatment of narcolepsy is unknown. Xywav is a mixture of calcium oxybate, magnesium oxybate, potassium oxybate, and sodium oxybate (gamma-hydroxybutyrate). Gamma-hydroxybutyrate (GHB) is an endogenous compound and metabolite of the neurotransmitter GABA. It is hypothesized that the therapeutic effects of Xywav on cataplexy and excessive daytime sleepiness are mediated through GABAB actions during sleep at noradrenergic and dopaminergic neurons, as well as at thalamocortical neurons.

    Side Effects

    Adverse effects associated with the use of Xywav in adults may include, but are not limited to, the following:

    • headache
    • nausea
    • dizziness
    • decreased appetite
    • parasomnia
    • diarrhea
    • hyperhidrosis
    • anxiety
    • vomiting

    Adverse effects associated with the use of Xywav in pediatrics may include, but are not limited to, the following:

    • enuresis
    • nausea
    • headache
    • vomiting
    • weight decreased
    • decreased appetite
    • dizziness

    The Xywav drug label comes with the following Black Box Warning: Central Nervous System Depression: Xywav is a CNS depressant, and respiratory depression can occur with Xywav use. Abuse and Misuse: The active moiety of Xywav is oxybate or gamma-hydroxybutyrate (GHB). Abuse or misuse of illicit GHB is associated with CNS adverse reactions, including seizure, respiratory depression, decreased consciousness, coma, and death. Xywav is available only through a restricted program called the Xywav REMS.

    Indication 1 - for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy

    approved July of 2020

    Dosing/Administration

    Adult Dosing Information:

    • The recommended starting dosage is 4.5 grams (g) per night administered orally, divided into two doses: 2.25 g at bedtime and 2.25 g taken 2.5 to 4 hours later.
    • Increase the dosage by up to 1.5 g per night per week (e.g., 0.75 g at bedtime and 0.75 g taken 2.5 to 4 hours later), to the recommended dosage range of 6 g to 9 g per night.
    • The dosage may be gradually titrated based on efficacy and tolerability.
    • Some patients may achieve better responses with unequal doses at bedtime and 2.5 to 4 hours later.
    • Doses higher than 9 g per night have not been studied and ordinarily should not be administered.

    Pediatric Dosing Information: For pediatric patients 7 years of age and older, Xywav is administered orally twice per night. The recommended starting pediatric dosage, titration regimen, and maximum total nightly dosage are based on patient weight. Please see drug label for weight specifications. The dosage may be gradually titrated based on efficacy and tolerability. Doses higher than 9 g per night have not been studied and ordinarily should not be administered.

    Clinical Trial Results

    The FDA approval of Xywav was based on two phase 3 clinical trials: one in adults and one in pediatrics. 

    Adults: A global, double-blind, placebo-controlled, randomized-withdrawal, multicenter study evaluated the efficacy and safety of JZP-258 in the treatment of cataplexy and EDS in adults with narcolepsy. The primary endpoint was the change in the weekly number of cataplexy attacks, and the key secondary endpoint was the change in the Epworth Sleepiness Scale (ESS) score with JZP-258 compared to placebo. The study enrolled 201 participants and randomized 134 participants, comprising a heterogeneous population, which included those previously treated with sodium oxybate and naïve to sodium oxybate, with or without other anticataplectic treatments. During the double-blind withdrawal period, there was a significant increase in median weekly number of cataplexy attacks in participants randomized to placebo compared with participants randomized to JZP-258 (median [Q1, Q3]: 2.35 versus 0.00 [−0.49, 1.75], respectively. At the end of the double-blind withdrawal period, there was a significant increase in median ESS scores in participants randomized to placebo compared with participants randomized to JZP- 258 (median [Q1, Q3]: 2.0 versus 0.0, respectively.

    Pediatrics: The effectiveness of Xyrem in the treatment of cataplexy and excessive daytime sleepiness in pediatric patients 7 years of age and older with narcolepsy was established in a double-blind, placebo-controlled, randomized-withdrawal study. The study was conducted in 106 pediatric patients (median age: 12 years; range: 7 to 17 years) with a baseline history of at least 14 cataplexy attacks in a typical 2-week period prior to any treatment for narcolepsy symptoms. Of the 106 patients, 2 did not receive study drug and 63 patients were randomized 1:1 either to continued treatment with Xyrem or to placebo. Randomization to placebo was stopped early as the efficacy criterion was met at the pre-planned interim analysis. The primary efficacy measure was the change in frequency of cataplexy attacks. Pediatric patients taking stable dosages of Xyrem who discontinued Xyrem treatment and were randomized to placebo during the double-blind treatment period experienced a statistically significant increase in weekly cataplexy attacks compared with patients who were randomized to continue treatment with Xyrem. Patients randomized to receive placebo during the double-blind treatment period experienced a statistically significant worsening of EDS compared with patients randomized to continue receiving Xyrem. 

    Indication 2 - Idiopathic Hypersomnia (IH) in adults

    approved August of 2021

    Dosing/Administration

    Xywav can be administered as a twice or once nightly regimen in adults.

    • Twice nightly: Initiate dosage at 4.5 g or less per night orally, divided into two doses. Titrate to effect in increments of up to 1.5 g per night per week, up to 9 g total nightly dose.
    • Once nightly: Initiate dosage at 3 g or less per night orally, as one dose. Titrate to effect in increments of up to 1.5 g per night per week, up to 6 g total nightly dose

    Clinical Trial Results

    This FDA approval is based on the global Phase 3 double-blind, multicenter, placebo-controlled, randomized withdrawal study that demonstrated the efficacy and safety of Xywav for the treatment of idiopathic hypersomnia in adults (n=154, 115 of whom were evaluable for efficacy data). In the study, Xywav demonstrated statistically significant and clinically meaningful differences compared to placebo in change in the primary endpoint of Epworth Sleepiness Scale score and secondary endpoints of Patient Global Impression of Change and the Idiopathic Hypersomnia Severity Scale. 

    Approval Date: 2020-07-01
    Company Name: Jazz Pharmaceuticals
    Back to Listings

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing